Martin T. Speth

Martin T. Speth

Auto-generated profile, based on publicly available information

Martin T. Speth

Department Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, 0371 Oslo, Norway

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MSMartin T. Speth
Martin T. Speth
URUrska Repnik
Urska Repnik
EMElisabeth Müller
Elisabeth Müller
JSJulia Spanier
Julia Spanier
UKUlrich Kalinke
Ulrich Kalinke
GGGareth Griffiths
Gareth Griffiths

26 January 2022 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
NDNils-Jørgen Knudsen Dal
Nils-Jørgen Knudsen Dal
MSMartin Speth
Martin Speth
KJKerstin Johann
Kerstin Johann
MBMatthias Barz
Matthias Barz
CBClaire Beauvineau
Claire Beauvineau
NANoelia Alonso-Rodriguez
Noelia Alonso-Rodriguez
With the increasing emergence of drug-resistant Mycobacterium tuberculosis strains, new and effective antibiotics against tuberculosis (TB) are urgently needed. However, the high frequency of poorly water-soluble compounds among hits in high-throughput drug screening campaigns is a major obstacle in drug discovery. Moreover, in vivo testing using conventional animal TB models, such as mice, is time consuming and costly, and represents a major bottleneck in lead compound discovery and development. Here, we report the use of the zebrafish embryo TB model for evaluating the in vivo toxicity and efficacy of five poorly water-soluble nitronaphthofuran derivatives, which were recently identified as possessing anti-TB activity in vitro. To aid solubilization, compounds were formulated in biocompatible polymeric micelles (PMs). Three of the five PM-formulated nitronaphthofuran derivatives showed low toxicity in vivo, significantly reduced bacterial burden and improved survival in infected zebrafish embryos. We propose the zebrafish embryo TB-model as a quick and sensitive tool for evaluating the in vivo toxicity and efficacy of new anti-TB compounds during early stages of drug development. Thus, this model is well suited for pinpointing promising compounds for further development.